AVITA Medical to Announce Second Quarter 2024 Financial Results
July 11 2024 - 3:10PM
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage
regenerative medicine company focused on first-in-class devices for
wound care management and skin restoration, today announced that it
will report its second quarter 2024 financial results after the
close of the U.S. financial markets on Thursday, August 8, 2024.
AVITA Medical will host a conference call and webcast that day at
1:30 p.m. Pacific Time (Friday, August 9, 2024, at 6:30 a.m.
Australian Eastern Standard Time) to discuss its financial results
and recent business highlights.
The live webcast will be accessible through AVITA Medical’s
Investor Relations website at ir.avitamedical.com. To participate
by telephone, please register in advance to receive dial-in details
and a personal PIN using this link. A replay of the webcast will be
available shortly after the live event on the Investor Relations
website.
About AVITA Medical, Inc.AVITA Medical® is a
commercial-stage regenerative medicine company transforming the
standard of care in wound care management and skin restoration with
innovative devices. At the forefront of our platform is the RECELL®
System, approved by the U.S. Food and Drug Administration for the
treatment of thermal burn wounds and full-thickness skin defects,
and for repigmentation of stable depigmented vitiligo lesions.
RECELL harnesses the regenerative properties of a patient’s own
skin to create Spray-On Skin™ Cells, delivering a transformative
solution at the point-of-care. This breakthrough technology serves
as the catalyst for a new treatment paradigm enabling improved
clinical outcomes. AVITA Medical also holds the exclusive rights to
market, sell, and distribute PermeaDerm®, a biosynthetic wound
matrix, in the United States.
In international markets, the RECELL System is approved to
promote skin healing in a wide range of applications including
burns, full-thickness skin defects, and vitiligo. The RECELL System
is TGA-registered in Australia, has received CE-mark approval in
Europe and has PMDA approval in Japan.
To learn more, visit www.avitamedical.com.
Authorized for release by the Chief Financial Officer of AVITA
Medical, Inc.
Investor & Media Contact:
Jessica Ekeberg
Phone +1-661-904-9269
investor@avitamedical.com
media@avitamedical.com
Avita Medical (NASDAQ:RCEL)
Historical Stock Chart
From Dec 2024 to Jan 2025
Avita Medical (NASDAQ:RCEL)
Historical Stock Chart
From Jan 2024 to Jan 2025